SECTION TITLE API
31. Petereit A, Saal C. What is the solubility of my compound? Assessing solubility for pharmaceutical research and development compounds. Am Pharm Rev. 2011;14:68-73.
32. Hoellke B, Arlt M, Saal C. Comparison of nephelometric, UV-spectroscopic and HPLC methods for high-throughput determination of aqueous drug solubility in mictrotiter plates. Anal Chem. 2009;81:3165-3172.
33. Wan H, Holmen AG. High-throughput screening of physicochemical properties and in-vitro ADME profi ling in drug discovery. Comb Chem High Through Screen. 2009;12:315-329.
34. Alsenz J, Kansy M. High-throughput solubility measurement in drug discovery and development. Adv Drug Deliv Rev. 2008;59:546-567.
35. Pitt A. High-throughput screening to determine aqueous drug solubility. Pharm Disc. 2005;5:46-49.
36. Kerns EH. High-throughput physicochemical profi ling for drug discovery. J Pharm Sci. 2001;90:1838-1858.
37. Petereit A, Saal C. Optimizing solubility: kinetic versus thermodynamic solubility— temptations and risks. Eur J Pharm Sci. 2012;47,589-595.
38. Sugano K, Kato T, Suzuki K, Keiko K, Sujaku T, Mano T. High-throughput solubility measurement with automated polarized light microscopy analysis. J Pharm Sci. 2006;95:2114-2122.
39. Diakidou M, Vertzoni M, Goumas K, et al. Characterization of the contents of ascending colon to which drugs are exposed after oral administration to healthy adults. Pharm Res. 2009;26:2141-2151.
40. Kalantzi L, Goumas K, Kalioras V, Abrahamsson B, Dressman JB, Reppas C. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/ bioequivalence studies. Pharm Res. 2006;23:165-176.
41. Dimitrios P, Vertzoni, M, Goumas K, et al. Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults. Pharm Res. 2011;28:3145-3158.
42. Jantratid E, Janssen N, Reppas C, Dressman, JB. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm Res. 2008:25:1663-1676.
43. Ottaviani G, Gosling DJ, Pattisier C, Rodde S, Zhou L, Faller B. What is modulating solubility in simulated intestinal fl uids? Eur J Pharm Sci. 2010;41:452-457.
44. Avdeef A, Tsinman K, Tsinman O, Sun N, Voloboy D. Miniaturization of powder dissolution measurement and estimation of particle size. Chemistry & Biodiversity. 2009;6:1796-1811.
45. Becker A, Petereit A, Saal C. Gaining knowledge on drug absorption: gathering physicochemical data for PK simulations. Am Pharm Rev. 2012;15:1194-1198.
46. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science. 1997;276:122-126.
47. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutical drug classifi cation: The correlation of in-vitro drug product dissolution and in-vivo bioavailability. Pharm Res. 1995;12:413-420.
48. Buttler JM, Dressman JB. The developability classifi cation system: application of biopharmaceutical concepts to formulation development. J Pharm Sci. 2010;99:4940-4954.
49. Parrott N, Lave T. Computer models for predicting drug absorption. Drugs Pharm Sci. 2010;193:338-355.
David Elder, PhD, studied chemistry at Newcastle upon Tyne (BSc, MSc) before moving to Edinburgh to study for a PhD in Crystallography. Dr. Elder has 37 years of experience at a variety of diff erent pharmaceutical companies (Sterling, Syntex, and GSK). He is currently a director within the Scinovo group in GSK R&D focused on externalization. He has seven patents to his name.
Christoph Saal, PhD, studied chemistry at the Technical University of Darmstadt and graduated in Physical Chemistry. In 1999, he joined Merck KGaA, where he held several positions within Analytical and Medicinal Chemistry. Currently, Christoph Saal is heading a group focused on analytical and physicochemical characterization of New Chemical Entities.
The Choice is Yours! print edition digital edition
pharmoutsourcing.com
You can now choose the way in which you access the latest information in the pharmaceutical and biopharmaceutical contract services industry! Each option contains regular sections on contract
manufacturing, research, packaging, formulation/development services, analytical testing, APIs, stability testing, clinical research and other areas, now with the convenience and flexibility to suit your schedule!
Visit
www.mypharmoutsourcing.com for digital and print subscriptions and
www.pharmoutsourcing.com for articles and additional web-only content
TM
A CompareNetworks, Inc. Publication 10150 Lantern Road, Suite 150 Fishers, IN 46037
pharmoutsourcing.com | 41 | March/April 2015
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78